GlassScriptPhysician profile
Randall N Smith
NPI 1427056555
$3,768.78
in general payments reported to CMS, 2019-2025
30 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $330 · 2021: $537 · 2022: $540 · 2023: $287 · 2024: $268 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $802.77 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $758.33 | 2019-2023 | Relistor |
| Scilex Pharmaceuticals INC. | $432.26 | 2019-2025 | Ztlido |
| Biodelivery Sciences International, INC. | $311.00 | 2019-2021 | |
| Zyla Life Sciences, INC. | $245.57 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $172.01 | 2019 | |
| Horizon Therapeutics Plc | $134.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $90.96 | 2019-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $81.17 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $79.68 | 2021-2022 | |
| Daiichi Sankyo INC. | $74.34 | 2019 | |
| Averitas Pharma INC. | $70.78 | 2025 | Qutenza |
| Electronic Waveform Lab, INC. | $70.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.71 | 2019 | |
| Assertio Therapeutics, INC. | $42.22 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.12 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.87 | 2025 | |
| Redhill Biopharma INC. | $34.23 | 2021 | |
| Valinor Pharma, LLC | $32.58 | 2023-2024 | Movantik |
| Mdd US Operations, LLC | $27.23 | 2019 | |
| Virtus Pharmaceuticals LLC | $26.84 | 2021 | |
| Ermi LLC | $26.83 | 2022 | |
| Almatica Pharma LLC | $22.98 | 2022 | |
| Grt US Holding, INC. | $20.58 | 2021 | |
| Ibsa Pharma INC. | $19.64 | 2020 | |
| Kaleo, INC. | $16.01 | 2019 | |
| Shionogi INC | $14.28 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $13.77 | 2019 | |
| Forte Bio-Pharma LLC | $13.39 | 2022 | |
| West Therapeutics Development, LLC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.